Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C2639
http://purl.obolibrary.org/obo/NCIT_C2639
|
|---|---|
| Preferred Name | Taurolidine |
| Definitions |
A synthetic broad-spectrum antibiotic with antibacterial, anticoagulant and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent's anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic broad-spectrum antibiotic with antibacterial, anticoagulant and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent's anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis. |
|---|---|
| prefLabel | Taurolidine
|
| label | Taurolidine
|
| PDQ_Closed_Trial_Search_ID | 38354
|
| code | C2639
|
| prefixIRI | NCIT:C2639
|
| in_subset | |
| Preferred_Name | Taurolidine
|
| FDA_UNII_Code | 8OBZ1M4V3V
|
| Contributing_Source | FDA
|
| Chemical_Formula | C7H16N4O4S2
|
| Maps_To | Taurolidine
|
| CAS_Registry | 19388-87-5
|
| NCI_Drug_Dictionary_ID | 38354
|
| Legacy Concept Name | Taurolidine
|
| type | |
| ALT_DEFINITION | A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called anti-infectives.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38354
|
| Accepted_Therapeutic_Use_For | Bronchiectasis; Catheter-Related Sepsis; Otitis Media; Peritonitis; Thoracic Empyema
|
| Semantic_Type |
Pharmacologic Substance
Antibiotic
|
| UMLS_CUI | C0144567
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |